08:00 , Mar 5, 2012 |  BC Week In Review  |  Company News

Lantheus, Beijing Double-Crane deal

Lantheus and Beijing Double-Crane will co-develop Lantheus' Definity perflutren injectable suspension in China to assess cardiovascular disease under an exclusive, 15-year deal. Double-Crane will be responsible for conducting trials and Lantheus will provide regulatory support...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Clinical News

Oxygent perflubron: Phase IIb discontinued

ALLP discontinued a double-blind, placebo-controlled, dose-escalation, French Phase IIb trial in 128 patients in order to focus on developing Oxygent in China. Beijing Double-Crane Pharmaceutical Co. Ltd. (Beijing, China), which has Chinese rights to Oxygent,...
00:50 , Oct 14, 2005 |  BC Extra  |  Company News

Alliance names DeFranco president

ALLP hired Jack DeFranco as president and COO. Previously, DeFranco was SVP and COO at Imcor (ICPH). The company's lead product is Oxygent perflubron, an intravenous oxygen-carrying perfluorocarbon emulsion. ALLP expects to begin a European...
07:00 , May 23, 2005 |  BC Week In Review  |  Company News

Alliance Pharmaceutical, Beijing Double-Crane deal

Beijing Double-Crane received Chinese development rights to ALLP's Oxygent perflubron oxygen carrier to avoid blood transfusions during surgery. ALLP will receive an upfront payment and is eligible for milestones and royalties. Beijing Double-Crane is responsible...
07:00 , Apr 11, 2005 |  BC Week In Review  |  Company News

Alliance Pharmaceutical, Beijing Double-Crane deal

The companies signed a memorandum of understanding under which Beijing Double-Crane would receive Chinese development rights to ALLP’s Oxygent perflubron oxygen carrier to avoid blood transfusions during surgery. If the deal is finalized, ALLP would...